Sayre Therapeutics offers a Docetaxel formulation with the efficacy of conventional Docetaxel minus the side effects associated with the solvent.
An anti-neoplastic agent approved for the treatment of Breast cancer, Prostate cancer, Gastric cancer and Head & Neck cancer.
Solvent free Docetaxel formulated using TPGS (Vitamin-E) as an excipient.
Obviates the preparation of the drug before infusion
In a clinical trial, Solfredoc® was shown to be associated minimal/nil hypersensitivity reactions.
across the blood brain-barrier with high drug encapsulation efficiency, cell uptake, cytotoxicity and desired bio-distribution of the formulated drug.
* Incidence of Hypersensitivity reactions only
Copyright ©2025. All Rights Reserved
